Arnold & Porter Advises Insmed In Exclusive Global Rights Agreement With AstraZeneca Involving Experimental Respiratory Drug

October 7, 2016

Washington, DC, October 7, 2016 -- Arnold & Porter LLP represented Insmed Incorporated in all aspects of its recent $150 million licensing agreement with AstraZeneca that gives Insmed exclusive rights globally to AZD7986, an experimental, early stage respiratory drug designed to stop an enzyme that regulates inflammation in the respiratory system and plays a key role in pulmonary diseases such as non-cystic fibrosis bronchiectasis. The transaction, which closed on October 5, reflected a deal value of $150M in achievable milestones with double-digit royalties. Under the deal, AstraZeneca also may negotiate a future agreement with Insmed to sell AZD7986 for chronic obstructive pulmonary disease or asthma.

Arnold & Porter's Kristen Riemenschneider and Alejandra Parra-Orlandoni led the legal team, which included Daniel Kracov, Keith Korenchuk, Cynthia Mann, Samuel Witten, Barbara Wootton, Vanessa Tabler, Ewan Townsend and Abeba Habtemariam.

Email Disclaimer